IDRX, Inc., a wholly owned subsidiary of GSK, LLC
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Explore linked clinical trials.1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, metastatic malignant neoplasm, neoplasm | Active, not recruiting | Phase 1 | 2026-10-05 | NCT05489237 |